Always confirm benefits directly with your insurer before assuming any reimbursement
In addition to cardiovascular benefits, dual GLP-1/amylin therapy is now being studied in various obesity-related conditions like nonalcoholic steatohepatitis, obstructive sleep apnea, chronic kidney disease, and heart failure with preserved ejection fraction, suggesting that these drugs could be used as a cornerstone therapy for the management of comprehensive metabolic syndrome rather than for just one indication
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
However, always consult a healthcare provider before use
Rubisco complex large subunit (RbsL) stained with Coomassie Brilliant Blue (CBB) was used as a loading control (bottom blot)
Wegovy (Semaglutide 2.4 mg) Wegovy is the version of semaglutide thats officially approved by Health Canada for chronic weight management